http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1514561-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c36819c054f29562209fd22c3d23ff0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da54f7ebbd2d9d8a82f92aca4d1b4e48 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1045 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate | 2003-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1514561-A1 |
| titleOfInvention | Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B |
| abstract | A specific binding member that binds human ED-B, wherein thenspecific binding member is labelled with an isotope selectednfrom the group consisting of 76 Br, 77 Br, 123 I, 124 I, 131 I and 211 Atnand comprises an antigen-binding site that comprises annantibody VH domain and an antibody VL domain, wherein thenantibody VH domain is selected from the group consisting ofnthe L19 VH domain, and a VH domain comprising a VH CDR1, a VHnCDR2 and a VH CDR3, wherein the VH CDR3 is the L19 VH CDR3 ofnSEQ ID NO. 3, the VH CDR1 is optionally L19 VH CDR1 of SEQ IDnNO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO.n2; and wherein the antibody VL domain is optionally selectednfrom the group consisting of the L19 VL domain, and a VLndomain comprising a VL CDR1, a VL CDR2 and a VL CDR3, whereinnthe VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6, the VL CDR1 isnoptionally L19 VL CDR1 of SEQ ID NO. 4, and the VL CDR2 isnoptionally L19 VL CDR2 of SEQ ID NO. 5; the L19 VH domain andnL19 VL domain sequences being disclosed in Pini et al. (1998)n J. Biol. Chem . 273: 21769-21776; wherein the specific bindingnmember comprises a mini-immunoglobulin comprising saidnantibody VH domain and antibody VL domain fused to ε S2 -CH4 andndimerized or comprises a whole IgG1 antibody molecule; alsonmethods and uses employing such a specific binding member. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8613930-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10494431-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9498541-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017201655-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2019202961-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11046762-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9061995-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2009243010-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2281006-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2281006-A1 |
| priorityDate | 2003-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 176.